Humira was AbbVie’s largest revenue line in fiscal 2017, bringing in $18.43B of $28.22B (65%).
| Products and Services | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2017 |
|---|---|---|---|---|---|---|
| Humira | $12.54B | $14.01B | $18.43B | |||
| H U M I R A | — | — | — | |||
| Revenue, Net | — | — | — | |||
| Dyslipidemia Products | — | — | — | |||
| Imbruvica | — | $754.00M | $2.57B | |||
| All Other | $1.96B | $1.40B | $998.00M | |||
| Other Products | — | — | — | |||
| Hcv | — | $1.64B | $1.27B | |||
| Androgel | $934.00M | $694.00M | $577.00M | |||
| Andro Gel | — | — | — | |||
| Kaletra | $870.00M | $700.00M | $423.00M | |||
| Lupron | $778.00M | $826.00M | $829.00M | |||
| Synagis | $835.00M | $740.00M | $738.00M | |||
| Synthroid | $709.00M | $755.00M | $781.00M | |||
| Sevoflurane | $550.00M | $474.00M | $410.00M | |||
| Creon | $516.00M | $632.00M | $831.00M | |||
| Duodopa | $220.00M | $231.00M | $355.00M | |||
| Viekira | $48.00M | — | — | |||
| Total | $19.96B | $22.86B | $28.22B |
AbbVie brought in $28.22B from its 12 revenue lines in fiscal 2017, the year ended December 31, 2017. That was up 23.4% from $22.86B in fiscal 2015, the previous year with figures. Humira was the largest at $18.43B (65.3%), ahead of Imbruvica at $2.57B (9.1%) and Hcv at $1.27B (4.5%). The other nine revenue lines brought in $5.94B combined.
Compared with fiscal 2015, the previous year with figures, Imbruvica grew fastest, up 241.2% to $2.57B, while All Other fell the most, down 28.8% to $998.00M.
AbbVie began breaking out Imbruvica in fiscal 2015 and Hcv in fiscal 2015. AbbVie stopped reporting Viekira as a separate revenue line after fiscal 2014, when it brought in $48.00M.
Calculated Under Revenue Guidance In Effect Before Topic 606 was AbbVie’s largest revenue line in fiscal 2018, bringing in $32.81B of $32.75B (100%).
| Initial Application Period Cumulative Effect Transition (2) | FY 2018 |
|---|---|
| Calculated Under Revenue Guidance In Effect Before Topic 606 | $32.81B |
| Difference Between Revenue Guidance In Effect Before & After Topic 606 | -$59.00M |
| Total | $32.75B |
AbbVie brought in $32.75B from its two revenue lines in fiscal 2018, the year ended December 31, 2018. Calculated Under Revenue Guidance In Effect Before Topic 606 was the largest at $32.81B (100.2%).
The total is net of Difference Between Revenue Guidance In Effect Before & After Topic 606, which took $59.00M off revenue in fiscal 2018.
United States was AbbVie’s largest region in fiscal 2017, bringing in $18.25B of $28.22B (65%).
| Geography | FY 2011 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|
| United States | $10.85B | $13.56B | $15.95B | $18.25B | ||
| Revenue, Net | — | — | — | — | ||
| All Other Countries | $3.90B | $4.00B | $3.89B | $4.08B | ||
| Other Countries | — | — | — | — | ||
| Germany | $1.04B | $1.08B | $1.10B | $1.16B | ||
| United Kingdom | $722.00M | $688.00M | $776.00M | $807.00M | ||
| Japan | $581.00M | $599.00M | $770.00M | $764.00M | ||
| France | $584.00M | $597.00M | $713.00M | $730.00M | ||
| Spain | $534.00M | $618.00M | $589.00M | $521.00M | ||
| Canada | $551.00M | $551.00M | $624.00M | $659.00M | ||
| Italy | $432.00M | $452.00M | $523.00M | $475.00M | ||
| The Netherlands | $345.00M | $334.00M | $352.00M | $362.00M | ||
| Brazil | $435.00M | $376.00M | $355.00M | $410.00M | ||
| Total | $19.96B | $22.86B | $25.64B | $28.22B |
AbbVie brought in $28.22B from its 11 regions in fiscal 2017, the year ended December 31, 2017. That was up 10.1% from $25.64B in fiscal 2016. United States was the largest at $18.25B (64.7%), ahead of All Other Countries at $4.08B (14.5%) and Germany at $1.16B (4.1%). The other eight regions brought in $4.73B combined.
Compared with fiscal 2016, United States grew fastest, up 14.4% to $18.25B, while Japan fell the most, down 0.8% to $764.00M. From fiscal 2014 to 2017, combined revenue from these regions grew from $19.96B to $28.22B, a compound annual growth rate of 12.2%. United States' share of the total rose from 54.3% to 64.7%.
AbbVie (ABBV) reports its revenue by products and services, by initial application period cumulative effect transition (2) and by geography. In fiscal 2017, Humira was its largest revenue line, bringing in $18.43B (65.3% of the total), followed by Imbruvica at $2.57B (9.1%).
Humira was AbbVie's largest revenue line in fiscal 2017, bringing in $18.43B, or 65.3% of the $28.22B total across its 12 revenue lines.
United States was AbbVie's largest region in fiscal 2017, bringing in $18.25B, or 64.7% of the $28.22B total across its 11 regions.
Among AbbVie's regions that make up at least 2% of revenue, United States grew fastest in fiscal 2017, up 14.4% from $15.95B to $18.25B.
Every figure comes from AbbVie's annual financial filings, as reported. Each line keeps the name AbbVie gives it, and years follow its fiscal calendar.
AbbVie's revenue by products and services goes back to fiscal 2011, with figures through fiscal 2017. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.